China Universal Asset Management Co. Ltd. Buys 3,855 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

China Universal Asset Management Co. Ltd. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,124 shares of the biopharmaceutical company’s stock after buying an additional 3,855 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $7,400,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Pinnacle Wealth Planning Services Inc. grew its stake in Alnylam Pharmaceuticals by 60.4% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 446 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 168 shares in the last quarter. North Dakota State Investment Board raised its stake in shares of Alnylam Pharmaceuticals by 8.3% during the 3rd quarter. North Dakota State Investment Board now owns 4,082 shares of the biopharmaceutical company’s stock worth $1,007,000 after purchasing an additional 313 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $234,000. Maxi Investments CY Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $3,479,000. Finally, BG Investment Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $2,498,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. BMO Capital Markets reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Truist Financial cut their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Stifel Nicolaus cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 target price for the company. in a research note on Thursday. Jefferies Financial Group boosted their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research report on Tuesday, September 8th. Finally, Chardan Capital restated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $355.10.

Alnylam Pharmaceuticals Stock Down 25.1%

ALNY opened at $174.00 on Friday. The business has a 50 day moving average price of $237.78 and a 200 day moving average price of $287.22. Alnylam Pharmaceuticals, Inc. has a twelve month low of $172.31 and a twelve month high of $479.79. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a market cap of $23.28 billion, a P/E ratio of 32.34 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up about 17% year over year and above expectations. Adjusted earnings also exceeded consensus, while the company maintained its fiscal 2026 outlook for product sales. Alnylam Reports 17% Q3 Revenue Growth
• Positive Sentiment: Management expects 2026 TTR franchise sales of roughly $4.2 billion to $4.5 billion, supported by continued demand for Amvuttra. The company also cited positive conviction in nucresiran and continued progress across its RNAi pipeline. Alnylam TTR Sales and TRITON-CM Update
• Neutral Sentiment: The $16.26 reported EPS beat was unusually large because of an approximately $1.9 billion tax benefit, making the headline result less indicative of recurring operating performance. Alnylam Q3 Tax Windfall
• Negative Sentiment: U.S. sales growth for Amvuttra and Onpattro reportedly slowed, raising concerns about the pace of the company’s core TTR franchise despite the maintained outlook. Alnylam Sales Growth Slows
• Negative Sentiment: Alnylam expanded the TRITON-CM heart-disease study for nucresiran to about 2,250 patients while retaining an expected launch around 2030. The larger trial may strengthen evidence, but it increases development demands and reinforces the long wait before a potential revenue contribution. Alnylam Nucresiran Trial Expansion
• Negative Sentiment: Stifel downgraded ALNY to Hold with a $225 price target, while Needham cut its target to $243 from $357, citing a less favorable risk-reward profile. Analysts also flagged potential policy and pricing risks. Stifel Downgrades Alnylam

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.